Therapeutic monoclonal antibodies: Trends in development and approval in the US

Current Opinion in Molecular Therapeutics

Volumn 4, Issue 2, 2002, Pages 110-118

  Reichert, Janice M ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antineoplastic; Clinical development; Food and drug administration approval; Immunological; Immunonetherapy; Monoclonal antibody

Indexed keywords

ABCIXIMAB; ALEMTUZUMAB; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; CANCER VACCINE; CAPECITABINE; CEAVAC; CETUXIMAB; CHIMERIC ANTIBODY; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPRATUZUMAB; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; HUMAN MONOCLONAL ANTIBODY; IBRITUMOMAB TIUXETAN; IMMUNOLOGIC AGENT; INFLIXIMAB; INTERLEUKIN 2 RECEPTOR ANTIBODY; IRINOTECAN; MONOCLONAL ANTIBODY; OKT 3; OMALIZUMAB; ORTHOCLONE; PALIVIZUMAB; PREDNISONE; RECOMBINANT PROTEIN; RITUXIMAB; TOSITUMOMAB; TRASTUZUMAB; UNINDEXED DRUG; VINCRISTINE;

ADULT; ALLERGIC RHINITIS; ANTIGEN ANTIBODY COMPLEX; ARTICLE; AUTOIMMUNE DISEASE; CANCER; CARDIOTOXICITY; CONTROLLED STUDY; DRUG APPROVAL; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; FOOD AND DRUG ADMINISTRATION; GRAFT REJECTION; HEART MUSCLE ISCHEMIA; HUMAN; IMMUNOTHERAPY; LOWER RESPIRATORY TRACT INFECTION; SEPSIS; LEGAL ASPECT; REVIEW; UNITED STATES;

ANTIBODIES, MONOCLONAL; DRUG APPROVAL; HUMAN; IMMUNOTHERAPY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; HUMANS;

EID: 0035997958     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Continuous cultures of fused cells secreting antibody of predefined specificity
2. Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains
3. Production of functional chimaeric mouse/human antibody
4. Replacing the complementarity-determining regions in a human antibody with those from a mouse
5. Human lymphocyte hybridomas and monoclonal antibodies
6. The effects of the Prescription Drug User Fee Act and the Food and Drug Administration Modernization Act on the development and approval of therapeutic medicines
7. Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H
8. From laboratory to clinic: The story of CAMPATH-1
9. Clinical development of therapeutic medicines: A biopharmaceutical versus pharmaceutical product comparison
10. Fast tract product designation under the Food and Drug Administration Modernization Act: The industry experience
11. Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guerin
12. Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen
13. Anticancer therapy targeting the erbB family of receptor tyrosine kinases
14. A phase II study of the bispecific antibody MDX-210 (anti-HER2 × CD64) with GM-CSF in HER2+ advanced prostate cancer
15. Approval summary: Gemtuzumab ozogamicin in relapsed acute myeloid leukemia
16. Mylotarg Study Group: Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse
17. Current use and future development of gemtuzumab ozogamicin
18. Immunotherapy of non-Hodgkin's lymphomas
19. Antibody-targeted immunotherapy for treatment of malignancy
20. Rituximab: The first monoclonal antibody approved for the treatment of lymphoma
21. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma
22. Pharmacology and therapeutic use of trastuzumab in breast cancer
23. Trastuzumab in the treatment of metastatic breast cancer: Anticancer therapy versus cardiotoxicity
24. Progress in CLL, chemotherapy, antibodies and transplantation
25. Biologic therapy for psoriasis: A brief history, II
26. Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBL
27. Update on D2E7: A fully human anti-tumour necrosis factor alpha monoclonal antibody
28. Effects of treatment with a fully human anti-tumour necrosis factor alpha monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFα in patients with rheumatoid arthritis
29. Anti-TNFα therapy of rheumatoid arthritis: What have we learned?
30. The UK Antegren Study Group: The effect of anti-[alpha]4 integrin antibody on brain lesion activity in MS
31. A randomized placebo-controlled trial of a humanized monoclonal antibody to α4 integrin in active Crohn's disease
32. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma
33. Experiences with monoclonal antibody therapy for allergic asthma
34. Omalizumab Seasonal Allergic Rhinitis Trial Group: Effect of omalizumab on symptoms of seasonal allergic rhinitis: A randomized controlled trial
35. Experience with monoclonal antibodies in allergic mediated disease: Seasonal allergic Rhinitis
36. Efficacy of OKT3 as primary therapy for histologically confirmed acute renal allograft rejection
37. The Phase III Daclizumab Study Group: Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation
38. The Global Simulect Study Group: Reduced acute rejection and superior 1-year renal allograft survival with basiliximab in patients with diabetes mellitus
39. Treatment of Crohn's disease with infliximab